Technical Data

168198
Clone Type
Polyclonal
Host
Rabbit
Source
Human
Conjugate
HRP
Isotype
IgG
Grade
Affinity Purified
Applications
E IHC WB
Crossreactivity
Hu Mo
Shipping Temp
Blue Ice
Storage Temp
-20°C
Rabbit Anti-GDF15 (Growth/Differentiation Factor 15, GDF-15, Placental Bone Morphogenetic Protein, Placental TGF-beta, Macrophage Inhibitory Cytokine 1, MIC-1, Prostate Differentiation Factor, NSAID-activated Gene 1 Protein, NAG-1, NSAID-regulated Gene 1 Protein, NRG-1, MIC1, PDF, PLAB, PTGFB) (HRP)
NAG-1, GDF15, MIC-1, nonsteroidal anti-inflammatory drug-activated gene, NSAID-activated gene 1 protein, growth differentiation factor 15, macrophage inhibitory compound 1, prostate-derived factor

Non-steroidal anti-inflammatory drug (NSAID)activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-b) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. Induced expression of NAG-1 results in stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.

Applications
Suitable for use in ELISA, Western Blot and Immunohistochemistry. Other applications not tested.
Recommended Dilution
ELISA: 1:10,000-1:50,000 Western Blot: 1:1000-1:5000 Immunohistochemistry: 1:500-1:2500 Optimal dilutions to be determined by the researcher.
Storage and Stability
Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile dH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Labeled with horseradish peroxidase (HRP). Sodium azide is a potent inhibitor of peroxidase and should not be added to HRP conjugates. HRP conjugates are sensitive to light.
Immunogen
Synthetic peptide corresponding to human NAG-1 at C-terminal.
Form
Supplied as a lyophilized powder in 0.02M PBS, pH 7.2, 0.01% gentamicin sulfate, 10mg/ml BSA. Reconstitute with sterile dH2O or PBS. Labeled with horseradish peroxidase (HRP).
Purity
Purified by immunoaffinity chromatography.
Specificity
Recognizes human Nag-1 Peroxidase Conjugated. Species Crossreactivity: mouse.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

References
No references available
USBio References
No references available
United States Biological | 4 Technology Way | Salem, MA 01970
Phone 800-520-3011 | Fax 978-594-8052 | Website www.usbio.net